The infectious disease therapeutics market would grow at a CAGR of 4.23% over the predicted time frame. The market is expected to increase in value from US$ 119.87 Bn in 2022 to US$ 167 Bn in 2030.
The on infectious disease therapeutics Market, which provides a business strategy, research & development activities, concise outline of the market valuation, valuable insights pertaining to market share, size, supply chain analysis, competitive landscape and regional proliferation of this industry.
Download Free Sample@ https://www.precedenceresearch.com/sample/2056
Report Scope of the Infectious Disease Therapeutics Market
| Report Coverage | Details |
| Market Size in 2022 | USD 119.87 Billion |
| Market Size by 2030 | USD 167 Billion |
| Growth Rate from 2022 to 2030 | CAGR of 4.23% |
| Base Year | 2021 |
| Forecast Period | 2022 to 2030 |
| Segments Covered | Mode of Treatment, Target Organism, Infection Type, Distribution Channel and Geography |
A recent report provides crucial insights along with application based and forecast information in the Global Infectious disease therapeutics Market. The report provides a comprehensive analysis of key factors that are expected to drive the growth of this market. This study also provides a detailed overview of the opportunities along with the current trends observed in the Infectious disease therapeutics market.
A quantitative analysis of the industry is compiled for a period of 10 years in order to assist players to grow in the market. Insights on specific revenue figures generated are also given in the report, along with projected revenue at the end of the forecast period.
Companies and Manufacturers Covered
The study covers key players operating in the market along with prime schemes and strategies implemented by each player to hold high positions in the industry. Such a tough vendor landscape provides a competitive outlook of the industry, consequently existing as a key insight. These insights were thoroughly analysed and prime business strategies and products that offer high revenue generation capacities were identified. Key players of the global Infectious disease therapeutics market are included as given below:
Infectious disease therapeutics Market Key Players
- Pfizer Inc. (U.S.)
- GlaxoSmithKline plc. (U.K)
- Merck & Co. (U.S.)
- F. Hoffmann-La Roche Ltd (Switzerland)
- AstraZeneca (U.K)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Sanofi (France)
Market Segments
By Mode of Treatment
- Vaccines
- Drugs
By Target Organism
- Antifungal
- Antiviral
- Antibacterial
- Anti-parasite
- Others
By Infection Type
- Viral
- Parasitic
- Fungal
- Bacterial
- Others
By Distribution Channel
- Clinic
- Hospitals
- Others
By Geography
- North America
- U.S.
- Canada
- Europe
- U.K.
- Germany
- France
- Asia-Pacific
- China
- India
- Japan
- South Korea
- Malaysia
- Philippines
- Latin America
- Brazil
- Rest of Latin America
- Middle East & Africa (MEA)
Report Objectives
- To define, describe, and forecast the global infectious disease therapeutics market based on product, and region
- To provide detailed information regarding the major factors influencing the growth of the market (drivers, opportunities, and industry-specific challenges)
- To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the total market
- To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of market segments with respect to four main regions—North America, Europe, Asia Pacific and the Rest of the World (RoW)2
- To strategically profile key players and comprehensively analyze their product portfolios, market shares, and core competencies3
- To track and analyze competitive developments such as acquisitions, expansions, new product launches, and partnerships in the infectious disease therapeutics market
Table of Content
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Infectious Disease Therapeutics Market
5.1. COVID-19 Landscape: Infectious Disease Therapeutics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Infectious Disease Therapeutics Market, By Mode of Treatment
8.1. Infectious Disease Therapeutics Market, by Mode of Treatment, 2022-2030
8.1.1. Vaccines
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Drugs
8.1.2.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Infectious Disease Therapeutics Market, By Target Organism
9.1. Infectious Disease Therapeutics Market, by Target Organism e, 2022-2030
9.1.1. Antifungal
9.1.1.1. Market Revenue and Forecast (2017-2030)
9.1.2. Antiviral
9.1.2.1. Market Revenue and Forecast (2017-2030)
9.1.3. Antibacterial
9.1.3.1. Market Revenue and Forecast (2017-2030)
9.1.4. Anti-parasite
9.1.4.1. Market Revenue and Forecast (2017-2030)
9.1.5. Others
9.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 10. Global Infectious Disease Therapeutics Market, By Infection Type
10.1. Infectious Disease Therapeutics Market, by Infection Type, 2022-2030
10.1.1. Viral
10.1.1.1. Market Revenue and Forecast (2017-2030)
10.1.2. Parasitic
10.1.2.1. Market Revenue and Forecast (2017-2030)
10.1.3. Fungal
10.1.3.1. Market Revenue and Forecast (2017-2030)
10.1.4. Bacterial
10.1.4.1. Market Revenue and Forecast (2017-2030)
10.1.5. Others
10.1.5.1. Market Revenue and Forecast (2017-2030)
Chapter 11. Global Infectious Disease Therapeutics Market, By Distribution Channel
11.1. Infectious Disease Therapeutics Market, by Distribution Channel, 2022-2030
11.1.1. Clinic
11.1.1.1. Market Revenue and Forecast (2017-2030)
11.1.2. Avastin
11.1.2.1. Market Revenue and Forecast (2017-2030)
11.1.3. Hospitals
11.1.3.1. Market Revenue and Forecast (2017-2030)
11.1.4. Others
11.1.4.1. Market Revenue and Forecast (2017-2030)
Chapter 12. Global Infectious Disease Therapeutics Market, Regional Estimates and Trend Forecast
12.1. North America
12.1.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.5. U.S.
12.1.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.1.6. Rest of North America
12.1.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.1.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.1.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.1.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2. Europe
12.2.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.5. UK
12.2.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.6. Germany
12.2.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.7. France
12.2.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.2.8. Rest of Europe
12.2.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.2.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.2.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.2.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3. APAC
12.3.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.5. India
12.3.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.6. China
12.3.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.7. Japan
12.3.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.3.8. Rest of APAC
12.3.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.3.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.3.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.3.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4. MEA
12.4.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.5. GCC
12.4.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.6. North Africa
12.4.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.7. South Africa
12.4.7.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.7.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.7.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.7.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.4.8. Rest of MEA
12.4.8.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.4.8.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.4.8.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.4.8.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5. Latin America
12.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.5. Brazil
12.5.5.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.5.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.5.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.5.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
12.5.6. Rest of LATAM
12.5.6.1. Market Revenue and Forecast, by Mode of Treatment (2017-2030)
12.5.6.2. Market Revenue and Forecast, by Target Organism (2017-2030)
12.5.6.3. Market Revenue and Forecast, by Infection Type (2017-2030)
12.5.6.4. Market Revenue and Forecast, by Distribution Channel (2017-2030)
Chapter 13. Company Profiles
13.1. Pfizer Inc. (U.S.)
13.1.1. Company Overview
13.1.2. Product Offerings
13.1.3. Financial Performance
13.1.4. Recent Initiatives
13.2. GlaxoSmithKline plc. (U.K)
13.2.1. Company Overview
13.2.2. Product Offerings
13.2.3. Financial Performance
13.2.4. Recent Initiatives
13.3. Merck & Co. (U.S.)
13.3.1. Company Overview
13.3.2. Product Offerings
13.3.3. Financial Performance
13.3.4. Recent Initiatives
13.4. F. Hoffmann-La Roche Ltd (Switzerland)
13.4.1. Company Overview
13.4.2. Product Offerings
13.4.3. Financial Performance
13.4.4. Recent Initiatives
13.5. AstraZeneca (U.K)
13.5.1. Company Overview
13.5.2. Product Offerings
13.5.3. Financial Performance
13.5.4. Recent Initiatives
13.6. Mylan N.V. (U.S.)
13.6.1. Company Overview
13.6.2. Product Offerings
13.6.3. Financial Performance
13.6.4. Recent Initiatives
13.7. Novartis AG (Switzerland)
13.7.1. Company Overview
13.7.2. Product Offerings
13.7.3. Financial Performance
13.7.4. Recent Initiatives
13.8. Sanofi (France)
13.8.1. Company Overview
13.8.2. Product Offerings
13.8.3. Financial Performance
13.8.4. Recent Initiatives
Chapter 14. Research Methodology
14.1. Primary Research
14.2. Secondary Research
14.3. Assumptions
Chapter 15. Appendix
15.1. About Us
15.2. Glossary of Terms
Contact Us:
Precedence Research
Apt 1408 1785 Riverside Drive Ottawa, ON, K1G 3T7, Canada
Call: +1 774 402 6168
Email: sales@precedenceresearch.com
Website: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
0 Comments